Remibrutinib is an Orally Active BTK Inhibitor for Chronic Urticaria Research
Remibrutinib is a potent and orally active BTK inhibitor for Chronic urticaria (CU) research.
Remibrutinib is a potent and orally active BTK inhibitor for Chronic urticaria (CU) research.
Tubulointerstitial fibrosis is a chronic and progressive process affecting kidneys during aging and in chronic kidney disease (CKD). The US Centers for Disease Control and Prevention project that 47% of…
Chloroquine is an antimalarial and anti-inflammatory agent widely used to treat malaria and rheumatoid arthritis. Intersetingly, Chloroquine not only a excellent anti-inflammatory agent, but also demonstrates more activities about cancer,…
Oxidative stress describes an imbalance between reactive oxygen species (ROS) synthesis and antioxidants. Normally, cells possess antioxidant defense systems that include ROS degrading molecules (ROS scavengers), such as uric acid,…
An angiogenesis inhibitor is a substance that inhibits the growth of new blood vessels (angiogenesis). Some angiogenesis inhibitors are endogenous and a normal part of the body's control and others are obtained exogenously through pharmaceutical drugs or diet. While…
Darapladib is an orally active, selective and reversible Lp-PLA2 inhibitor, with an IC50 value of 0.25 nM.
REV-ERB is a member of the nuclear receptor (NR) superfamily of intracellular transcription factors. Besides, REV-ERB also is a key regulatory component of the circadian clock. Meanwhile, REV-ERB regulates the…
TLR9 is an important receptor existing in immune system cells (including dendritic cells, macrophages, and other antigen-presenting cells). TLR9 recognizes cellular DNA fragments containing unmethylated cytidine-phosphate-guanosine (CpG DNA) which only…
Glycosidases are enzymes catalyzing the hydrolysis of glycosidic bonds in complex sugars. They take part in the biosynthesis of the oligosaccharide chains and quality control mechanisms in the endoplasmic reticulum…
CD73, known as ecto-5′-nucleotidase (ecto-5′-NT, EC 3.1.3.5) is a glycosyl-phosphatidylinositol (GPI)-linked 70-kDa cell surface enzyme found in most tissues. Targeting CD73 results in favorable antitumor effects in pre-clinical models. Combined…